Brussels, 01/02/2006 (Agence Europe) - The European Commission has authorised the investment capital groups ABN Amro and L Capital 2 FCPR to take possession of Sanutri, a subsidiary of the Swiss group Novartis and which is active in the sales of diet food products (under the brand names "Gerblé", "Céréal", "Gerlinéa" and "Milical"), as the operation poses no problems in terms of competition. L Capital already controls Forté Pharma, a company which is active, mainly in France, in the sales of diet products in pharmacies and para-pharmacies, under its own name. Further to its investigation, the Commissioned noted only a limited number of overlaps in activities between Sanutri and Forté Pharma, mainly in the field of slimming products. Furthermore, the companies have different positions within the distribution networks and the products on offer. Sanutri achieves the vast majority of its sales to large and medium-sized department stores, from which Forte is completely absent. Moreover, the products sold by both companies respond to different needs.